Theratechnologies (THTX) Stock Price, News & Analysis

Written before these shares stopped trading.

Theratechnologies Inc. (historically traded on Nasdaq under the symbol THTX) is a commercial-stage specialty biopharmaceutical company focused on the commercialization of therapies that it describes as having the potential to redefine standards of care. According to company disclosures, Theratechnologies is a biopharmaceutical issuer whose activities center on prescription products and the management of specific comorbidities, particularly in people living with HIV. The company is headquartered in Montreal, Quebec, Canada and has been identified in public data as operating in the pharmaceutical preparation manufacturing segment of the broader manufacturing sector.

Based on information provided in regulatory filings and press releases, Theratechnologies has marketed tesamorelin for injection in the United States for the reduction of excess abdominal fat in adult patients with HIV and lipodystrophy. Earlier descriptions of the business also refer to the commercial product EGRIFTA and the later formulation EGRIFTA SV, as well as Trogarzo, an injection that refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Company materials describe Theratechnologies as concentrating on therapies that address complex metabolic and infectious disease-related needs.

Theratechnologies’ public communications highlight its focus on HIV-associated conditions, including excess visceral abdominal fat (EVAF) and lipodystrophy. The company has reported clinical and real-world data related to tesamorelin and EVAF in people with HIV, including analyses from the Visceral Adiposity Measurement and Observations Study (VAMOS) and a case series involving tesamorelin used alongside GLP-1 receptor agonists. These activities underscore its emphasis on understanding and managing metabolic complications in an aging HIV population.

Historically, Theratechnologies has also discussed development-stage or pipeline assets, including an F8 formulation associated with tesamorelin and oncology-related programs. Earlier descriptions mention candidates such as TH-1902 and TH-1904 for certain cancer indications. More recent disclosures indicate that the company decided to cease early-stage oncology research activities, with reduced spending in its oncology program and a greater focus on commercial and late-stage assets. Company filings also reference work on tesamorelin formulation development and human factor studies related to the F8 formulation.

Corporate transformation and acquisition by Future Pak

Theratechnologies underwent a significant corporate change following a sale process led by a special committee of its board of directors. On July 2, 2025, the company announced it had entered into a binding arrangement agreement with CB Biotechnology, LLC, an affiliate of Future Pak, LLC, pursuant to which the purchaser would acquire all issued and outstanding common shares of Theratechnologies for cash consideration plus contingent value rights (CVRs). Subsequent press releases dated September 12, 16, and 25, 2025 confirm shareholder approval, court approval, and the completion of the plan of arrangement under the Business Corporations Act (Québec).

On September 25, 2025, Theratechnologies announced the completion of its acquisition by CB Biotechnology, the affiliate of Future Pak. The transaction provided shareholders with cash per share and one CVR per share, with the CVRs tied to potential additional cash payments if specified milestones related to the company’s franchises are achieved. Following completion of the arrangement, it was announced that the common shares of Theratechnologies would be delisted from the Toronto Stock Exchange and from the Nasdaq Capital Market, and that the company would apply to cease to be a reporting issuer in Canada and deregister its shares under the U.S. Securities Exchange Act of 1934.

A Form 25 filed with the U.S. Securities and Exchange Commission on September 25, 2025, by Nasdaq Stock Market LLC, provides formal notification of the removal of Theratechnologies’ common shares from listing and registration under Section 12(b) of the Exchange Act. This filing confirms that the Nasdaq exchange has taken action to strike the class of securities from listing. As a result of the completed transaction and subsequent delisting steps, Theratechnologies has transitioned from a publicly traded issuer to a privately held company affiliated with Future Pak.

Therapeutic focus and HIV-related research

Theratechnologies’ communications emphasize its role in addressing HIV-related metabolic complications. The company has described tesamorelin for injection as a growth hormone–releasing factor analog approved in the United States for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. In 2025, Theratechnologies announced the availability of EGRIFTA WR (tesamorelin) for injection in the U.S., following U.S. Food and Drug Administration approval earlier that year. EGRIFTA WR is presented as a new formulation of tesamorelin for the reduction of excess abdominal fat in adult patients with HIV and lipodystrophy, and the company has indicated that this formulation will gradually replace EGRIFTA SV during a transition period.

In addition to regulatory and commercial updates, Theratechnologies has reported on scientific presentations at the American Conference for the Treatment of HIV (ACTHIV). These include analyses from the VAMOS study, which examined the relationship between excess visceral abdominal fat and muscle quality in people with HIV, and a case series evaluating the combined use of tesamorelin and GLP-1 receptor agonists in real-world clinical practice. Such communications illustrate the company’s interest in generating data on body composition, EVAF, and related metabolic outcomes in HIV populations.

Financial reporting and public company history

As a former dual-listed issuer on the Toronto Stock Exchange and the Nasdaq Capital Market, Theratechnologies regularly filed financial statements and management’s discussion and analysis (MD&A) on SEDAR+ in Canada and EDGAR in the United States. A press release dated July 9, 2025, summarizes revenue from products such as EGRIFTA SV and Trogarzo, cost of goods sold, research and development expenses, selling and general and administrative expenses, and adjusted EBITDA, referencing detailed figures available in the company’s interim consolidated financial statements and MD&A for the quarter ended May 31, 2025.

Those disclosures also describe the company’s assessment of its liquidity and ability to continue as a going concern, including commentary on cash balances, operating cash flows, and credit facilities. The company noted actions taken to address prior material uncertainty related to going concern and provided narrative explanations for changes in revenue, cost of goods sold, and research and development spending, including the impact of an EGRIFTA SV supply disruption and adjustments related to inventory provisions for the F8 formulation.

Status of the THTX symbol

For investors researching the historical THTX stock, it is important to recognize that Theratechnologies’ common shares have been acquired by an affiliate of Future Pak and are in the process of being delisted and deregistered as described in the company’s September 25, 2025 press release and the Nasdaq Form 25. The THTX ticker therefore represents a former listing rather than an actively traded public equity. Historical information on Theratechnologies as a public company, including prior financial statements, management proxy circulars, and material change reports, remains accessible through SEDAR+ and EDGAR under the company’s legacy profile.